Sun Pharma Submits SEBI Confirmation Certificate for Q3 FY26
Sun Pharmaceutical Industries Limited submitted a SEBI confirmation certificate for the quarter ended December 31, 2025. The certificate, received from registrar MUFG Intime India Pvt. Ltd., confirms the processing and listing of dematerialized securities.
This is a standard compliance filing required by SEBI and does not involve any new business developments, financial results, or corporate actions that would significantly affect the company's stock price.
The announcement is a routine regulatory filing regarding the confirmation of dematerialized securities and does not contain any information that would positively or negatively impact the company's stock.
Sun Pharmaceutical Industries Limited has submitted a confirmation certificate for the quarter ended 31 December 2025, as per Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.
The certificate was received from M/s. MUFG Intime India Pvt. Ltd., the company's Registrar & Share Transfer Agent. This confirmation pertains to the dematerialization of securities during the quarter. MUFG Intime India Pvt. Ltd. confirmed that securities received from depository participants for dematerialization were processed (accepted/rejected) and subsequently listed on the stock exchanges.
Furthermore, the registrar confirmed that the security certificates received for dematerialization were duly verified, mutilated, and cancelled. The name of the depositories was substituted as the registered owner in the company's register of members within the prescribed timelines. The company noted that no requests for rematerialization were received during this period.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.